A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

Prior treatment

• History of ≥2 primary malignancies within 5 years prior to informed consent.
• Received anti-tumor treatment within 4 weeks or within the 5 half-lives of the previous treatment (whichever is shorter) before dosing.
• Medication of other unmarketed investigational drugs or therapies within 4 weeks before dosing.
• Undergone major organ surgery (excluding biopsy) or significant trauma within 4 weeks before dosing or requiring elective surgery during the study.
• Vaccinated with attenuated live vaccines within 4 weeks before dosing.
• Treated with with systemic corticosteroids within 14 days before dosing.
• Known hypersensitivity or delayed allergic reaction to the investigational product or its components.
• Known alcohol or drug dependence.

Other illness

• Serious cardiovascular or cerebrovascular diseases.
• Severe lung disease affecting pulmonary function.
• Active infection requiring systemic therapy.
• Drug abuse or other medical/psychiatric condition that may interfere with study participation or results.

Other

• Central nervous system metastasis.
• Uncontrolled third-space effusion.
• Pregnant or breastfeeding women, or individuals planning to conceive.

• Voluntarily agrees to participate in the study and signs the informed consent form.
• Age ≥ 18 and ≤75 years, no restriction on gender.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Estimated life expectancy ≥ 3 months.
• Histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors.
• At least one measurable lesion per RECIST v1.1 criteria.
• Adequate bone marrow reserve and organ function.
• Eligible participants of childbearing potential (males and females) must agree to take highly reliable contraceptive measures with their partners during the study and within at least 12 weeks after the last dose.
  • \-